FDA Allows Outsourcing Facilities to Extend Beyond-Use Date for Repackaged Avastin

February 2, 2018: By Joan McKenna

Avastin is repackaged into smaller doses for IVT use.

The US FDA will allow outsourcing facilities to extend the beyond-use date (BUD) for repackaged Avastin if additional sterility testing is undertaken, the agency announced Jan. 19.

The FDA released the policy change in two published final guidance documents on compounding.

In response, the American Society of Cataract and Refractive Surgery said it was working with the ophthalmic community to identify the cost and time associated with the test and the opinions of outsourcers on the final guidance.

The current BUD for repackaged Avastin is 90 to 180 days, according to a Minnesota retina specialist.

Draft guidance released in February 2015 called for a BUD of no more than five days for biologics repackaged at 503B outsourcing facilities. The clock would start once the package was opened at an outsourcing facility for repackaging.

Critics said the short timetable would make it impossible for Avastin to be repackaged, labeled, shipped, handled, and used by a surgeon, much less tested for sterility.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

EyeGate’s EGP-437 for Post-Cataract Pain, Inflammation Produces Mixed Results in Phase IIb Trial

Second Sight Reports Record Number of Argus II Implants in Q4-2017, First Orion Implant in Human

Allergan Appoints Matthew Walsh as CFO

Ocunova Secures $500 Thousand From Two Firms to Pursue Dry Eye Treatment for Diabetic Patients

ReVision Optics Closes Doors; Raindrop Corneal Inlay No Longer Available

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023